EUR/USD 1.17136
-0.221%
Gold 4688.74
-0.559%
Oil 96.973
-1.762%
USD/JPY 157.877
0.170%
GBP/USD 1.35230
-0.122%
GBP/JPY 213.497
0.050%
Browse More
  • English
  • 简体中文
  • 繁體中文
  • Tiếng Việt
  • ไทย
  • Indonesia
Subscribe
Real-time News
The Saudi Defense Minister met with British National Security Advisor Jonathan Powell. They reviewed relevant issues of Saudi-British cooperation and discussed coordinated efforts to address regional challenges and de-escalate tensions.On May 14th, European Central Bank President Christine Lagarde stated that EU leaders must demonstrate courage and strengthen the EUs institutional foundations. In her speech, Lagarde emphasized the work done by her predecessor, Mario Draghi, in enhancing European competitiveness. She called on European leaders to implement Draghis recommendations and "break free from complacency." Lagarde and other ECB officials have repeatedly urged European governments to strengthen Europes economic and political foundations and enhance its autonomy. Last year, she stated that delaying measures to boost growth and allowing prosperity to continue to slip away was not only disappointing but also "irresponsible." Earlier this year, the ECB Governing Council called for "urgent collective action" to strengthen Europe, emphasizing the need to establish a savings and investment union, advance a digital euro, deepen the single market, introduce policies to promote innovation, and simplify legislation.Fitch Ratings expects BP (BP.N) to reach the lower end of its $14 billion to $18 billion net debt target range by the end of 2026. The Iran war has had a limited impact on BPs operations, but its credit profile is expected to be positively affected by rising oil and gas prices.Cisco (CSCO.O): Third-quarter product orders increased by 35% year-over-year, with growth in all regions and customer markets. Excluding orders from hyperscale cloud service providers, the growth rate was 19%. In the optical business, Acacias third-quarter orders exceeded $1 billion, representing triple-digit year-over-year growth.According to Business Insider, Amazon (AMZN.O) is laying off more employees this week, affecting its Selling Partner Services division.

AstraZeneca's nasal spray vaccine trial for COVID experiences a setback

Charlie Brooks

Oct 11, 2022 11:23

16.png


Tuesday, attempts by researchers from Oxford University and AstraZeneca (NASDAQ:AZN) Plc to manufacture a nasal-spray version of their jointly developed COVID-19 injection were hindered by the failure of first human tests to give the required degree of protection.


During the first of generally three phases of clinical testing, a minority of trial participants had an antibody response in their respiratory mucous membranes, according to a statement released by the University of Oxford on Tuesday.


In addition, the immune response measured in the blood was weaker than that caused by an arm injection.


Researchers from throughout the world have high hopes for nasal spray vaccinations against the coronavirus, as it is predicted that the method could prevent infection and illness by stimulating an immune response directly in the airways, where the virus enters the body.


In addition, the method would be less painful and easier to administer than injections.


In India and China, regulators have previously authorized the administration of drugs via the airways.


Last month, India's health minister approved Bharat Biotech's COVID-19 nasal spray vaccine, while China's medicines regulator approved CanSino Biologics Inc's COVID-19 inhaled vaccine on an emergency basis.


CanSino has said that its nebuliser-delivered vaccine can develop robust immunity to successfully restrict disease, but Bharat's trial findings are not yet available.


The British study included 30 unvaccinated patients and 12 volunteers who had previously undergone a normal two-dose immunization course.


In this study, the nasal spray did not perform as well as anticipated, according to Sandy Douglas, the trial's primary investigator at the Jenner Institute of Oxford University.


She went on to say, "We believe that delivery of vaccinations through the nose and lungs remains a viable option, but this study suggests that there will be challenges in making nasal sprays a reliable alternative."


During the AstraZeneca-funded trial, no severe adverse events or safety concerns were reported, according to the release.

Suggestion